These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23622099)

  • 21. Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.
    Rantalaiho V; Kautiainen H; Korpela M; Puolakka K; Blåfield H; Ilva K; Hannonen P; Leirisalo-Repo M; Möttönen T;
    Ann Rheum Dis; 2014 Apr; 73(4):788-90. PubMed ID: 24297374
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
    Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
    Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.
    Cannon GW; Wang BC; Park GS; Koenig A; Collier DH; Keystone EC
    Clin Exp Rheumatol; 2013; 31(6):919-25. PubMed ID: 24237999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial management of rheumatoid arthritis.
    Gramling A; O'Dell JR
    Rheum Dis Clin North Am; 2012 May; 38(2):311-25. PubMed ID: 22819086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteria.
    Kuriya B; Sun Y; Boire G; Haraoui B; Hitchon C; Pope JE; Thorne JC; Keystone EC; Bykerk VP;
    J Rheumatol; 2012 Jun; 39(6):1155-8. PubMed ID: 22505708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the management of rheumatoid arthritis.
    Dale J
    Scott Med J; 2015 Aug; 60(3):108-14. PubMed ID: 26122283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
    Caporali R; Scirè CA; Todoerti M; Montecucco C
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S9-13. PubMed ID: 24129129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
    Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
    Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.
    Steunebrink LM; Vonkeman HE; ten Klooster PM; Hoekstra M; van Riel PL; van de Laar MA
    Clin Rheumatol; 2016 Mar; 35(3):609-15. PubMed ID: 26852313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment.
    Wevers-de Boer KV; Heimans L; Visser K; Schouffoer AA; Molenaar ET; van Groenendael JH; Peeters AJ; Speyer I; Collée G; Huizinga TW; Allaart CF
    Rheumatology (Oxford); 2015 Aug; 54(8):1380-4. PubMed ID: 25687553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the optimal target for treat-to-target strategies in rheumatoid arthritis?
    Bergstra SA; Allaart CF
    Curr Opin Rheumatol; 2018 May; 30(3):282-287. PubMed ID: 29356697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Jun; 22(3):346-52. PubMed ID: 21960457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
    Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.
    Vázquez I; Graell E; Gratacós J; Cañete JD; Viñas O; Ercilla MG; Gómez A; Hernández MV; Rodríguez-Cros JR; Larrosa M; Sanmartí R
    Clin Exp Rheumatol; 2007; 25(2):231-8. PubMed ID: 17543147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
    Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
    Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.